WO2023051586A1 - Kras g12d抑制剂化合物及其制备方法和应用 - Google Patents

Kras g12d抑制剂化合物及其制备方法和应用 Download PDF

Info

Publication number
WO2023051586A1
WO2023051586A1 PCT/CN2022/122041 CN2022122041W WO2023051586A1 WO 2023051586 A1 WO2023051586 A1 WO 2023051586A1 CN 2022122041 W CN2022122041 W CN 2022122041W WO 2023051586 A1 WO2023051586 A1 WO 2023051586A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
optionally substituted
alkyl
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2022/122041
Other languages
English (en)
French (fr)
Inventor
邹昊
祝东星
祝伟
李正涛
Original Assignee
先声再明医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 先声再明医药有限公司 filed Critical 先声再明医药有限公司
Priority to CN202280065933.1A priority Critical patent/CN118043330A/zh
Publication of WO2023051586A1 publication Critical patent/WO2023051586A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the present invention relates to a KRAS G12D inhibitor compound or a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound or a stereoisomer or a pharmaceutically acceptable salt thereof, and the compound Use of a stereoisomer or a pharmaceutically acceptable salt thereof in the prevention or treatment of diseases or conditions associated with the KRAS G12D mutation.
  • RAS is a GTP-binding protein that is involved in the regulation of cell proliferation, cell differentiation, cell adhesion, cell apoptosis, and cell migration. Mutations in the RAS gene will result in permanently activated RAS proteins, even in the absence of incoming signals, leading to overactive signaling within the cell and, ultimately, potentially cancer.
  • the three RAS genes in humans (HRAS, KRAS and NRAS) are the most common oncogenes in human cancers, and about 20% of human tumors have activating RAS gene mutations (Targeting RAS signaling pathways in cancer therapy. Downward, J. Nat Rev Cancer. 2003, 3(1), 11–22). For the specific RAS gene mutation (KRAS G12C), it has been confirmed that it can be used to treat cancer.
  • Sotorasib has been approved by the FDA as a second-line treatment for non-small cell lung cancer with KRAS G12C mutation.
  • KRAS G12D mutation there is currently no sufficient safety for KRAS G12D mutation. and/or effective drugs, therefore, it is necessary to further develop new KRAS G12D inhibitors.
  • the present invention relates to a compound of formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof,
  • Ring B is selected from 8-10 membered nitrogen-containing heterocyclic groups optionally substituted by R , and the nitrogen-containing heterocyclic groups are in the form of bridged rings;
  • Ring A is a 5-6 membered heteroaryl ring, benzene ring, 4-7 membered heterocyclic ring or C 3 -C 6 cycloalkene ring, and the 5-6 membered heteroaryl ring, benzene ring, 4-7 membered heterocyclic ring or C 3 -C 6 cycloalkene ring is optionally substituted by R 4 ;
  • the C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 10 cycloalkyl or C 3 -C 10 cycloalkyloxy are optionally substituted by R 4a ;
  • R 3 is selected from C 6 -C 14 aryl and 5-14 membered heteroaryl, and the C 6 -C 14 aryl or 5-14 membered heteroaryl is optionally substituted by R 3a ;
  • X is selected from CR 5 and N;
  • R 5 is selected from H, halogen, OH, CN, NO 2 , NH 2 , NH(C 1 -C 3 alkyl), N(C 1 -C 3 alkyl) 2 , C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 2 -C 4 alkynyl, C 3 -C 10 cycloalkyl and C 3 -C 10 cycloalkyl Oxygen;
  • W is selected from O, NR 6 and a bond
  • R2 is selected from The R 2 is optionally substituted by R 7 ;
  • R 7 is selected from deuterium, halogen, OH, CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 10 cycloalkyl and C 3 -C 10 cycloalkyloxy, so The C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 10 cycloalkyl or C 3 -C 10 cycloalkyloxy are optionally substituted by R 7a ;
  • two R 3a and their respective connected atoms form a C 4 -C 6 cycloalkenyl or a 5-7 membered heterocyclic group, and the C 4 -C 6 cycloalkenyl or 5-7 membered heterocyclic group is optionally replaced by R 3d ;
  • R 1a , R 3b and R 6 are independently selected from H and C 1 -C 6 alkyl;
  • n is selected from 0, 1 and 2.
  • Ring B is selected from 8-membered nitrogen-containing heterocycloalkyl groups optionally substituted by R in the form of a bridged ring.
  • Ring B is selected from the following groups optionally substituted by R :
  • Ring B is selected from the following groups optionally substituted by R :
  • R 1a is selected from H and C 1 -C 3 alkyl.
  • R 1 is selected from halogen, OH, C 1 -C 3 alkyl and C 1 -C 3 alkoxy, and the C 1 -C 3 alkyl or C 1 -C 3 alkoxy is any is replaced by R 1b .
  • R 1b is selected from deuterium, halogen, OH, CN, and NH 2 .
  • R 1b is selected from halogen, OH and CN.
  • R1 is selected from halogen, OH, methyl, methoxy, CN, CNCH2- , CNCH2CH2- , and hydroxymethyl.
  • Ring B is selected from
  • Ring A is selected from the group consisting of 5-6 membered heteroaromatic rings, benzene rings, tetrahydropyridine rings, dihydropyran rings, cyclohexene, and cyclohexene dihydrogen rings optionally substituted by R4 . alkene.
  • ring A is selected from a benzene ring, a 6-membered heteroaromatic ring, a 6-membered heterocycle, and a C6 cycloalkene ring, and the benzene ring, a 6-membered heteroaryl ring, a 6-membered heterocycle, or a C6 cycloalkene ring Ring is optionally substituted with R4 .
  • ring A is selected from the following groups optionally substituted by R :
  • ring A is selected from the following groups optionally substituted by R :
  • ring A is selected from the following groups optionally substituted by R :
  • ring A is selected from the group consisting of optionally substituted by R
  • R 4a is selected from halogen, OH and CN.
  • R4 is selected from F, Cl, and methyl.
  • L is selected from O and a bond.
  • L is selected from a bond.
  • L is O.
  • R is selected from naphthyl, phenyl, and 5-10 membered heteroaryl optionally substituted with R 3a .
  • R is selected from naphthyl, phenyl, pyridyl, benzopyrrolyl, benzopyrazolyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolyl, benzo Isothiazolyl, benzimidazolyl and benzofuryl, the naphthyl, phenyl, pyridyl, benzopyrrolyl, benzopyrazolyl, benzothienyl, benzothiazolyl, quinolinyl , isoquinolinyl, benzisothiazolyl, benzimidazolyl or benzofuryl are optionally substituted by R 3a .
  • R is selected from naphthyl, phenyl, pyridyl, benzothienyl, and benzopyrazolyl, and the naphthyl, phenyl, pyridyl, benzothienyl, or benzopyrazolyl
  • the group is optionally substituted by R 3a .
  • R 3b is selected from H and C 1 -C 3 alkyl.
  • R 3c is selected from deuterium, halogen, OH, CN, NH 2 and C 1 -C 3 alkoxy.
  • R 3c is selected from F.
  • R 3d is selected from halogen, OH, C 1 -C 3 alkyl, and C 1 -C 3 alkoxy.
  • R 3a is selected from halogen, OH, CN, CF 3 , CHF 2 , methyl, hydroxymethyl, -CH 2 OCH 3 , ethyl, hydroxyethyl, 2,2,2-trifluoro Ethyl, 2,2-difluoroethyl, 2-fluoroethyl, n-propyl, isopropyl, 1-hydroxy-1-methylethyl, 1-F-1-methylethyl, 3- Fluoropropyl, isobutyl, -C(CH 3 )CH 2 CH 3 , methoxy, difluoromethoxy, trifluoromethoxy, isopropoxy, methylthio, trifluoromethylthio, CNCH 2 CH 2 -, NH 2 , NHCH 3 , N(CH 3 ) 2 , NHCH 2 CH 3 , Ethynyl, -C ⁇ C-CH 2 OH, -C ⁇ C-CH 2 NH 2
  • R 3a is selected from F, Cl, OH, ethynyl, CF 3 , methyl, ethyl, NH 2 and CN.
  • R is selected from
  • R 3 -L- is selected from
  • R 5 is selected from H, OH, CN, C 2 -C 4 alkynyl, C 1 -C 3 haloalkyl, and C 3 -C 6 cycloalkyl.
  • R 5 is selected from H, CN, C 2 -C 4 alkynyl, and C 1 -C 3 haloalkyl.
  • R 5 is selected from H, CN, and -C ⁇ CH.
  • W is O or NH.
  • W is O.
  • n 1
  • R is selected from the following groups optionally substituted by R :
  • R 2 is selected from the group optionally substituted by R 7
  • R 2 is selected from the group optionally substituted by R 7
  • R 7 is selected from halogen, OH, CN, C 1 -C 6 alkyl and C 1 -C 6 alkoxy, the C 1 -C 6 alkyl or C 1 -C 6 alkoxy The group is optionally substituted by R 7a .
  • R 7a is selected from deuterium, halogen, OH, CN, and NH 2 .
  • R 7 is selected from halogen and halogenated C 1 -C 6 alkyl.
  • R7 is selected from F.
  • R is selected from
  • W-(CH 2 ) n -R 2 is selected from
  • the compounds of formula (I) of the present invention are selected from compounds of formula (IIa):
  • ring A's is also optionally substituted by R 4
  • ring B, R 4 , L, R 3 , X, W, R 2 and n are as defined in formula (I).
  • the compounds of formula (I) of the present invention are selected from compounds of formula (IIb):
  • the compounds of formula (I) of the present invention are selected from compounds of formula (IIc):
  • ring A's is also optionally substituted by R 4
  • ring B, R 4 , L, R 3 , X, W, R 2 and n are as defined in formula (I).
  • the compound of formula (I) of the present invention is selected from the following compounds:
  • the present invention provides a pharmaceutical composition, which comprises the compound of formula (I) of the present invention or its stereoisomer or pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients.
  • the present invention provides a method for treating a disease or disorder associated with a KRAS G12D mutation in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer thereof to a mammal in need of such treatment, preferably a human. body or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • the present invention provides a method for treating tumors in mammals, comprising administering a therapeutically effective amount of a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable dose thereof to a mammal in need of the treatment, preferably a human. salt, or a pharmaceutical composition thereof.
  • the present invention provides the use of the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of medicines for preventing or treating diseases related to KRAS G12D mutation.
  • the present invention provides the use of the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of drugs for preventing or treating tumors.
  • the present invention provides the use of the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt, or its pharmaceutical composition in preventing or treating diseases related to KRAS G12D mutation.
  • the present invention provides the use of the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt, or its pharmaceutical composition in preventing or treating tumors.
  • the present invention provides the compound of formula (I) or its stereoisomer or pharmaceutically acceptable salt thereof, or its pharmaceutical composition for preventing or treating diseases related to KRAS G12D mutation.
  • the present invention provides a compound of formula (I) or its stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the prevention or treatment of tumors.
  • the disease associated with a KRAS G12D mutation is selected from a tumor.
  • the tumor is selected from cancer.
  • the cancer is selected from gastric cancer.
  • tautomer refers to isomers of functional groups resulting from the rapid movement of an atom in a molecule between two positions.
  • the compounds of the present invention may exhibit tautomerism.
  • Tautomeric compounds can exist in two or more interconvertible species. Tautomers generally exist in equilibrium and attempts to isolate a single tautomer usually result in a mixture whose physicochemical properties are consistent with the mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; in phenols, the enol form predominates.
  • the present invention encompasses all tautomeric forms of the compounds.
  • stereoisomer refers to isomers resulting from differences in the arrangement of atoms in a molecule in space, including cis-trans isomers, enantiomers and diastereomers.
  • the compounds of the present invention may have asymmetric atoms such as carbon atoms, sulfur atoms, nitrogen atoms, phosphorus atoms or asymmetric double bonds, so the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
  • Specific geometric or stereoisomeric forms may be cis and trans isomers, E and Z geometric isomers, (-)- and (+)-enantiomers, (R)- and (S )-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic or other mixtures thereof, such as enantiomers or diastereomers Enriched mixtures, all of the above isomers and mixtures thereof are within the definition of the compounds of the present invention.
  • asymmetric carbon atoms there may be additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms or asymmetric phosphorus atoms in substituents such as alkyl groups, and these isomers and their mixtures involved in all substituents are also included in within the definition of the compounds of the invention.
  • the compounds containing asymmetric atoms of the present invention can be isolated in optically pure form or in racemic form, the optically active form can be resolved from a racemic mixture, or synthesized by using chiral starting materials or chiral reagents .
  • substituted means that any one or more hydrogen atoms on the specified atom are replaced by a substituent, as long as the valence of the specified atom is normal and the substituted compound is stable.
  • ethyl is “optionally” substituted with halogen , meaning that the ethyl group can be unsubstituted ( CH2CH3 ), monosubstituted ( CH2CH2F , CH2CH2Cl , etc.), polysubstituted ( CHFCH2F , CH2CHF2 , CHFCH2Cl , CH2CHCl2 , etc. ) or fully substituted ( CF2CF3 , CF2CCl3 , CCl2CCl3 , etc.) . It will be appreciated by those skilled in the art that for any group containing one or more substituents, no sterically impossible and/or synthetically impossible substitution or substitution pattern is introduced.
  • any variable eg R 1 , R 4
  • its definition is independent at each occurrence. For example, if a group is substituted by 2 R4s , each R4 has independent options.
  • linking group When the number of a linking group is 0, such as -(CH 2 ) 0 -, it means that the linking group is a bond.
  • one of the variables is selected from chemical bond or non-existence, it means that the two groups connected are directly connected.
  • L in ALR 3 represents a bond, it means that the structure is actually AR 3 .
  • linking direction is arbitrary.
  • structural unit Ring A in is selected from
  • structural unit can either be can also be
  • Cm - Cn herein refers to having an integer number of carbon atoms in the range of mn.
  • C 1 -C 6 means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
  • alkyl refers to a hydrocarbon group having the general formula C n H 2n+1 , and the alkyl group may be straight or branched.
  • C 1 -C 6 alkyl is understood to mean a straight-chain or branched saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • alkyl group examples include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2- Methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-di Methylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, etc.
  • C 1 -C 3 alkyl is understood to mean a linear or branched saturated monovalent hydrocarbon radical having 1 to 3 carbon atoms.
  • the "C 1 -C 6 alkyl group” may include “C 1 -C 3 alkyl group”.
  • haloalkyl refers to a group in which any one or more hydrogen atoms in the alkyl group are replaced by halogen atoms. Where multiple hydrogen atoms are substituted, each halogen atom for substitution is selected independently of the other.
  • C 1 -C 3 haloalkyl refers to a group in which any one or more hydrogen atoms in the "C 1 -C 3 alkyl” are replaced by halogen atoms.
  • alkoxy refers to a monovalent group produced by the loss of a hydrogen atom on a hydroxyl group of a straight-chain or branched alcohol, which can be understood as “alkyloxy” or “alkyl-O-”.
  • C 1 -C 6 alkoxy can be understood as “C 1 -C 6 alkyloxy” or “C 1 -C 6 alkyl-O-”; the term “C 1 -C 3 alkoxy” Can be understood as “C 1 -C 3 alkyloxy” or "C 1 -C 3 alkyl-O-”.
  • the "C 1 -C 6 alkoxy” may further include "C 1 -C 3 alkoxy”.
  • haloalkoxy refers to a group in which any one or more hydrogen atoms in the alkoxy group are replaced by halogen atoms. Where multiple hydrogen atoms are substituted, each halogen atom for substitution is selected independently of the other.
  • C 1 -C 3 haloalkoxy refers to a group in which any one or more hydrogen atoms in "C 1 -C 3 alkoxy” are replaced by halogen atoms.
  • alkenyl refers to a linear or branched monovalent unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond.
  • C 2 -C 4 alkenyl is understood to mean a linear or branched unsaturated monovalent hydrocarbon group containing one or more double bonds and having 2, 3 or 4 carbon atoms, "C 2 -C 4 alkenyl” is preferably C 2 or C 3 alkenyl. It is understood that where the alkenyl group contains more than one double bond, the double bonds may be separated from each other or conjugated.
  • alkenyl group examples include, but are not limited to, vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, (E)-but-2-enyl , (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, isopropenyl, 2-methylprop-2-enyl, 1 -Methylprop-2-enyl, 2-methylprop-1-enyl, (E)-1-methylprop-1-enyl or (Z)-1-methylprop-1-enyl wait.
  • alkynyl refers to a linear or branched monovalent unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond.
  • C 2 -C 4 alkynyl is understood to mean a straight-chain or branched unsaturated monovalent hydrocarbon radical comprising one or more triple bonds and having 2, 3 or 4 carbon atoms.
  • Examples of “C 2 -C 4 alkynyl” include, but are not limited to, ethynyl (-C ⁇ CH), propynyl (-C ⁇ CCH 3 , -CH 2 C ⁇ CH), but-1-ynyl, but -2-ynyl or but-3-ynyl.
  • C 2 -C 4 alkynyl may include “C 2 -C 3 alkynyl", examples of “C 2 -C 3 alkynyl” include ethynyl (-C ⁇ CH), prop-1-ynyl (-C ⁇ CCH 3 ), prop-2-ynyl (propargyl).
  • alkynylene refers to a divalent group obtained by removing one more hydrogen atom from the "alkynyl”.
  • C 2 -C 4 alkynylene refers to a divalent group obtained by removing one hydrogen atom from the “C 2 -C 4 alkynyl”, examples include but are not limited to -C ⁇ C- , -C ⁇ C-CH 2 - and so on.
  • cycloalkyl refers to a fully saturated carbocyclic ring in the form of a monocyclic ring, a double ring, a bridged ring, or a spiro ring. Unless otherwise indicated, the carbocycle is typically a 3 to 10 membered ring.
  • C 3 -C 10 cycloalkyl is understood to mean a saturated monovalent monocyclic, fused, spiro or bridged ring having 3, 4, 5, 6, 7, 8, 9 or 10 carbons atom.
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo[2.2 .1] heptyl), bicyclo [2.2.2] octyl, adamantyl, spiro [4.5] decanyl, etc.
  • C 3 -C 10 cycloalkyl may include “C 3 -C 6 cycloalkyl”, and the term “C 3 -C 6 cycloalkyl” can be understood as representing a saturated monovalent monocyclic or bicyclic hydrocarbon ring, It has 3, 4, 5 or 6 carbon atoms, specific examples include but not limited to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and the like.
  • cycloalkyloxy can be understood as “cycloalkyl-O-”.
  • C 3 -C 10 cycloalkoxy may include “C 3 -C 6 cycloalkyloxy”.
  • cycloalkenyl refers to a non-aromatic monocyclic or polycyclic hydrocarbon group containing at least one carbon-carbon double bond.
  • C 3 -C 6 cycloalkenyl refers to a non-aromatic cyclic hydrocarbon having 3, 4, 5 or 6 carbon atoms as ring atoms and containing at least one carbon-carbon double bond.
  • Specific examples of C 3 -C 6 cycloalkenyl include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
  • C 3 -C 6 cycloalkenyl may include “C 4 -C 6 cycloalkenyl”, and "C 4 -C 6 cycloalkenyl” may further include “C 6 cycloalkenyl”.
  • 4-10 membered heterocyclic group refers to a heterocyclic group with 4, 5, 6, 7, 8, 9 or 10 ring atoms, and its ring atoms contain 1-5 ring atoms independently selected from the above-mentioned heteroatoms or heteroatom groups.
  • “4-10 membered heterocyclic group” includes “8-10 membered heterocyclic group”, “8-10 membered heterocyclic group” further includes “4-7 membered heterocyclic group”, “4-7 membered heterocyclic group” It further includes "5-7 membered heterocyclic group”, and "5-7 membered heterocyclic group” further includes 6-membered heterocyclic group.
  • 4-membered heterocyclic groups include but are not limited to azetidinyl or oxetanyl
  • 5-membered heterocyclic groups include but are not limited to tetrahydrofuranyl, dioxolyl , pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, 4,5-dihydrooxazolyl or 2,5-dihydro-1H-pyrrolyl
  • specific examples of 6-membered heterocyclic groups include but Not limited to tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, tetrahydropyridyl or 4H-[1,3,4] Thiadiazinyl
  • specific examples of 7-membered heterocyclyl include, but are not limited to, diazepanyl.
  • the heterocyclic group can also be a bicyclic group, wherein, specific examples of the 5,5-membered bicyclic group include, but are not limited to, hexahydrocyclopenta[c]pyrrol-2(1H)-yl; 5,6-membered bicyclic group Specific examples include, but are not limited to, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4 ,3-a]pyrazinyl or 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl.
  • the heterocyclic group may be a benzofused cyclic group of the above-mentioned 4-7 membered heterocyclic group, specific examples include but not limited to dihydroisoquinolyl and the like.
  • “4-7 membered heterocyclyl” may further include “4-6 membered heterocyclyl", “5-6 membered heterocyclyl”, “4-7 membered heterocycloalkyl”, “4-6 membered heterocyclic Alkyl”, "5-6 membered heterocycloalkyl” and other ranges.
  • some bicyclic heterocyclic groups partially contain a benzene ring or a heteroaromatic ring, the heterocyclic groups as a whole are still non-aromatic.
  • nitrogen-containing heterocyclic group refers to a "heterocyclic group” containing at least one nitrogen atom as a ring atom.
  • 4-10 membered heterocycloalkyl refers to a heterocycloalkyl group with 4, 5, 6, 7, 8, 9 or 10 ring atoms, and its ring atoms contain 1-5 ring atoms independently selected from the above The heteroatom or heteroatom group.
  • 4-10 membered heterocycloalkyl includes "8-10 membered heterocycloalkyl”.
  • nitrogen-containing heterocycloalkyloxy refers to a "heterocycloalkyl” containing at least one nitrogen atom as a ring atom.
  • aryl refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated ⁇ -electron system.
  • Aryl groups can have 6-14 carbon atoms or 6-10 carbon atoms.
  • C 6 -C 14 aryl is understood as a monovalent aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 14 carbon atoms.
  • C aryl rings with 6 carbon atoms
  • C aryl such as phenyl ; or rings with 9 carbon atoms (“C aryl”), such as indenyl; or rings with 10 carbon atoms ring (“C 10 aryl”), such as naphthyl; or a ring with 13 carbon atoms (“C 13 aryl”), such as fluorenyl; or a ring with 14 carbon atoms (“C 14 aryl”) ”), such as anthracenyl.
  • C 6 -C 10 aryl should be understood as a monovalent or partially aromatic all-carbon monocyclic or bicyclic group having 6 to 10 carbon atoms.
  • C 6 -C 14 aryl may include "C 6 -C 10 aryl”.
  • heteroaryl refers to an aromatic monocyclic or fused polycyclic ring system, which contains at least one ring atom selected from N, O, and S, and an aromatic ring group whose ring atoms are C.
  • heteroaryl refers to an aromatic monocyclic or fused polycyclic ring system, which contains at least one ring atom selected from N, O, and S, and an aromatic ring group whose ring atoms are C.
  • 5-14 membered heteroaryl is understood to include monovalent monocyclic or bicyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 rings Atoms, especially 5 or 6 or 9 or 10 ring atoms, and it contains 1-5, preferably 1-3 heteroatoms independently selected from N, O and S.
  • heteroaryl is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiazolyl Diazolyl, etc.
  • benzo derivatives such as benzofuryl, benzothienyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazole base, indazolyl, indolyl or isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl, etc., and their benzo derivatives, such as quinolinyl, quinazole Linyl or isoquinolinyl, etc.; or azocinyl, indolizinyl, purinyl, etc.
  • 5-6 membered heteroaryl refers to an aromatic ring system having 5 or 6 ring atoms, and which contains 1-3, preferably 1-2, heteroatoms independently selected from N, O and S.
  • 5-14 membered heteroaryl may include “5-10 membered heteroaryl", “5-10 membered heteroaryl” may further include “5-6 membered heteroaryl”, “5-6 membered heteroaryl” "Aryl” may further include “6-membered heteroaryl”.
  • halo or halogen refers to fluorine, chlorine, bromine or iodine.
  • hydroxyl refers to a -OH group.
  • cyano refers to a -CN group.
  • mercapto refers to a -SH group.
  • amino refers to a -NH2 group.
  • nitro refers to a -NO2 group.
  • terapéuticaally effective amount means (i) treating or preventing a particular disease, condition or disorder, (ii) alleviating, ameliorating or eliminating one or more symptoms of a particular disease, condition or disorder, or (iii) preventing or delaying The amount of a compound of the invention for the onset of one or more symptoms of a particular disease, condition or disorder described herein.
  • the amount of a compound of the invention that constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art according to its own knowledge and this disclosure.
  • pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without excessive Toxicity, irritation, allergic reaction, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to salts of pharmaceutically acceptable acids or bases, including salts formed between compounds and inorganic or organic acids, and salts formed between compounds and inorganic or organic bases.
  • composition refers to a mixture of one or more compounds of the present invention or their salts and pharmaceutically acceptable excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound of the invention to an organism.
  • pharmaceutically acceptable excipients refers to those excipients that have no obvious stimulating effect on the organism and will not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and/or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like.
  • the present invention also includes isotopically labeled compounds of the present invention that are identical to those described herein, but with one or more atoms replaced by an atom of an atomic mass or mass number different from that normally found in nature.
  • isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl, etc.
  • isotopically labeled compounds of the invention are useful in compound and/or substrate tissue distribution assays. Tritiated (ie3H ) and carbon-14 (ie14C ) isotopes are especially preferred for their ease of preparation and detectability.
  • Positron-emitting isotopes such as 15 O, 13 N, 11 C, and 18 F, can be used in positron emission tomography (PET) studies to determine substrate occupancy.
  • Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • the pharmaceutical composition of the present invention can be prepared by combining the compound of the present invention with suitable pharmaceutically acceptable auxiliary materials, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders , granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.
  • Typical routes of administration of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, Intramuscular, subcutaneous, intravenous administration.
  • the pharmaceutical composition of the present invention can be produced by methods well known in the art, such as conventional mixing methods, dissolving methods, granulating methods, emulsifying methods, freeze-drying methods and the like.
  • the pharmaceutical composition is in oral form.
  • the pharmaceutical compositions can be formulated by mixing the active compounds with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present invention to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions and the like for oral administration to patients.
  • Solid oral compositions can be prepared by conventional methods of mixing, filling or tabletting. It can be obtained, for example, by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if desired, and processing the mixture into granules to obtain tablets Or the core of the sugar coating.
  • Suitable auxiliary materials include but are not limited to: binders, diluents, disintegrants, lubricants, glidants or flavoring agents, etc.
  • the pharmaceutical composition may also be adapted for parenteral administration as a suitable unit dosage form of sterile solutions, suspensions or lyophilized products.
  • the daily dosage is 0.01 mg/kg to 200 mg/kg body weight, preferably 0.05 mg/kg to 50 mg/kg body weight, more preferably 0.1 mg/kg Up to 30 mg/kg body weight, in single or divided doses.
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by their combination with other chemical synthesis methods, and the methods well known to those skilled in the art Equivalent alternatives, preferred embodiments include but are not limited to the examples of the present invention.
  • some compounds of general formula (I) of the present invention can be prepared by those skilled in the art of organic synthesis through the following synthetic route 1 or synthetic route 2:
  • X 1 is selected from CH, CR 4 or N
  • X 2 is selected from halogen
  • ring B, L, R 3 , R 4 , W, R 2 and n are as defined in formula (I);
  • the compound shown in formula (I-1) obtains the compound shown in formula (I-2) through substitution reaction;
  • Compound shown in formula (I-2) is under basic condition,
  • the compound shown in the formula (I-3) is obtained through a carbonyl insertion coupling reaction;
  • the compound shown in the formula (I-3) and the compound shown in the formula (I-4) are first reacted under tetrahydrofuran and then added ammonia methanol Solution, obtain compound shown in formula (I-5) through cyclization reaction;
  • Compound shown in formula (I-5) obtains compound shown in formula (I-6) through substitution reaction under phosphorus oxychloride condition;
  • Formula (I The compound shown in -6) obtains the compound shown in the formula (I-7) through a substitution reaction under basic conditions;
  • the compound shown in the formula (I-7) obtains the compound shown in the formula (I-8) through a substitution reaction under basic conditions
  • some compounds of the general formula (I) of the present invention can be prepared by those skilled in the field of organic synthesis through the following synthetic route 3:
  • R 4 , L, R 3 , ring B, W, R 2 and n are as defined in formula (I);
  • the compound shown in formula (II-1) and formula (I-9) obtains the compound shown in formula (II-2) through C-C coupling reaction in the presence of catalyst under basic conditions; formula ( The compound shown in II-2) and the compound shown in formula (II-3) obtain the compound shown in formula (II-4) through substitution reaction under basic conditions; the compound shown in formula (II-4) and the compound shown in formula (II -5)
  • the compound shown in -5) obtains the compound shown in the formula (II-6) through cyclization reaction under alkaline conditions;
  • a compound shown in formula (II-7) is obtained through a substitution reaction, and then the compound shown in formula (II-7) is subjected to a substitution reaction under basic conditions to obtain a compound shown in formula (II-8); or formula (II-6)
  • the shown compound can directly obtain the compound shown in the formula (II-8) through a substitution reaction in the presence of a catalyst under alkaline conditions according to the 2 path; the compound shown in the formula (II-8)
  • ratios indicated for mixed solvents are volume mixing ratios. Unless otherwise stated, % means wt%.
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • DIEA N,N-diisopropylethylamine
  • Boc tert-butoxycarbonyl
  • TIPS triisopropylsilyl
  • TBAF tetrabutylammonium fluoride
  • 1,4-dioxane Pd(dppf)Cl 2 : [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
  • M mol/liter.
  • the following eluents can be mixed eluents formed by two or more solvents, and the ratio is the volume ratio of each solvent.
  • “0-10% methanol/dichloromethane” means that in the gradient elution process, mixed eluents
  • the volume ratio of methanol and dichloromethane in the mixture is 0:100 ⁇ 10:100.
  • Example 1 4-(4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-((octahydro-2aH-pyrrolo[2,1 ,5-cd]pyrrolazin-2a-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalene-2-ol (compound 1) preparation
  • Step 1 Preparation of octahydro-2aH-pyrrolo[2,1,5-cd]pyrrolazine-2a-carboxylate hydrochloride (1b)
  • Step 3 3-(7-Chloro-8-fluoro-2-((octahydro-2aH-pyrrolo[2,1,5-cd]pyrrolazin-2a-yl)methoxy)pyrido[4, Preparation of tert-butyl 3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1e)
  • Step 4 3-(8-Fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)- 2-((Octahydro-2aH-pyrrolo[2,1,5-cd]pyrrolazin-2a-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8 -Preparation of tert-butyl diazabicyclo[3.2.1]octane-8-carboxylate (1g)
  • Step 5 4-(4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-((octahydro-2aH-pyrrolo[2,1 ,5-cd]pyrrolazin-2a-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalene-2-ol (compound 1) preparation
  • the cell AGS used in the experiment is a cell line with KRAS G12D mutation.
  • Cells were subcultured with Ham's F-12K (Kaighn's) medium plus 10% FBS. Cells with low cell numbers were frozen in liquid nitrogen.
  • Detection kit 3D Cell Viability Assay is a homogeneous detection method for detecting the number of viable cells in 3D cell microtissues by quantitatively measuring ATP.
  • the kit produces a luminescent signal that is proportional to the amount of ATP present, which is directly proportional to the number of cells.
  • the total experimental system of the dilution program was 50 ⁇ L, the initial concentration was 50 ⁇ M, 3-fold dilution, 10 concentration points, and the total volume of the compound and DMSO was 250 nL.
  • 30 ⁇ L of culture solution was added to each well, centrifuged at 1000 rpm for 5 minutes in a centrifuge, and then cultured in a cell culture incubator for 7 days.
  • 25 ⁇ L of 3D CTG reagent was added to each well, shaken for 10 minutes, and then placed at room temperature in the dark for 30 minutes.
  • Chemiluminescence signal The Luminescence signal in each well was measured using an Envision plate reader (emission wavelength 400-700 nm). 100% inhibition was defined as the level of inhibition of proliferation of cells treated with 10 ⁇ M of positive compound.
  • the positive compound is the compound of Example 252 prepared according to the method described in Example 252 of the specification of patent application WO2021041671A1.
  • the formula for calculating the inhibition rate of the compound on cell proliferation is:
  • Cell proliferation inhibition rate% (Average_H–Sample)/(Average_H–L) x 100%
  • Sample refers to the signal value read in each well of the drug-dosed group.
  • HillSlope is the slope coefficient of the curve.
  • the inhibitory activity of the compounds of the present invention on AGS cell proliferation was determined by the above tests, and the measured IC 50 values are shown in Table 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开了作为KRAS G12D抑制剂的化合物或其立体异构体或其可药用盐，所述化合物具有式(I)所示的结构。还公开了所述式(I)化合物或其立体异构体或其可药用盐的制备方法、含有所述化合物或其立体异构体或其可药用盐的药物组合物、以及所述化合物或其立体异构体或其可药用盐在预防或治疗与KRAS G12D突变相关的疾病或病症中的用途。

Description

KRAS G12D抑制剂化合物及其制备方法和应用
本发明要求2021年9月29日向中国国家知识产权局提交的，专利申请号为202111151279.X，发明名称为“KRAS G12D抑制剂化合物及其制备方法和应用”的在先申请的优先权。上述在先申请的全文通过引用的方式结合于本发明中。
技术领域
本发明涉及作为KRAS G12D抑制剂化合物或其立体异构体或其可药用盐、其制备方法、含有该化合物或其立体异构体或其可药用盐的药物组合物、以及所述化合物或其立体异构体或其可药用盐在预防或治疗与KRAS G12D突变相关的疾病或病症中的用途。
背景技术
RAS是一种GTP结合蛋白，参与调节细胞增殖、细胞分化、细胞粘附、细胞凋亡和细胞迁移等过程。RAS基因的突变将导致永久激活的RAS蛋白，即使在没有传入信号的情况下，也将导致细胞内过度活跃的信号传导，并最终可能导致癌症。人类中的三个RAS基因(HRAS、KRAS和NRAS)是人类癌症中最常见的致癌基因，约20％的人类肿瘤中存在激活的RAS基因突变(Targeting RAS signalling pathways in cancer therapy.Downward,J.Nat Rev Cancer.2003,3(1),11–22)。针对其中特定的RAS基因突变(KRAS G12C)目前已被证实可以用于治疗癌症，如Sotorasib已被FDA批准作为KRAS G12C突变的非小细胞肺癌的二线治疗，但是，针对KRAS G12D突变目前缺乏足够安全和/或有效的药物，因此，有必要进一步研发新的KRAS G12D抑制剂。
发明内容
本发明涉及式(I)化合物或其立体异构体或其药学上可接受的盐，
Figure PCTCN2022122041-appb-000001
其中，
环B选自任选被R 1取代的8-10元含氮杂环基，所述含氮杂环基呈桥环形式；
R 1选自卤素、OH、＝O、CN、C 1-C 6烷基、C 1-C 6烷氧基、HC(＝O)-、-CO 2R 1a、-CON(R 1a) 2和5-6元杂芳基，其中所述C 1-C 6烷基、C 1-C 6烷氧基或5-6元杂芳基任选被R 1b取代；
环A为5-6元杂芳环、苯环、4-7元杂环或C 3-C 6环烯环，所述5-6元杂芳环、苯环、4-7元杂环或C 3-C 6环烯环任选被R 4取代；
R 4选自氘、卤素、OH、＝O、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基和C 3-C 10环烷基氧基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基或C 3-C 10环烷基氧基任选被R 4a取代；
L选自O、-C(＝O)-和键；
R 3选自C 6-C 14芳基和5-14元杂芳基，所述C 6-C 14芳基或5-14元杂芳基任选被R 3a取代；
X选自CR 5和N；
R 5选自H、卤素、OH、CN、NO 2、NH 2、NH(C 1-C 3烷基)、N(C 1-C 3烷基) 2、C 1-C 3烷基、C 1-C 3卤代烷基、C 1-C 3烷氧基、C 1-C 3卤代烷氧基、C 2-C 4炔基、C 3-C 10环烷基和C 3-C 10环烷基氧基；
W选自O、NR 6和键；
R 2选自
Figure PCTCN2022122041-appb-000002
所述R 2任选被R 7取代；
R 7选自氘、卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基和C 3-C 10环烷基氧基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基或C 3-C 10环烷基氧基任选被R 7a取代；
R 3a选自卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4烯基、C 2-C 4炔基、-CH 2C(＝O)N(R 3b) 2、-(C 2-C 4亚炔基)-N(R 3b) 2、N(R 3b) 2、C 3-C 10环烷基和5-6元杂芳基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4烯基、C 2-C 4炔基、C 2-C 4亚炔基、C 3-C 10环烷基或5-6元杂芳基任选被R 3c取代；
或者，两个R 3a与其各自相连的原子一起形成C 4-C 6环烯基或5-7元杂环基，所述C 4-C 6环烯基或5-7元杂环基任选被R 3d取代；
R 1a、R 3b和R 6独立地选自H和C 1-C 6烷基；
R 1b、R 3c、R 3d、R 4a和R 7a独立地选自氘、卤素、OH、CN、＝O、NH 2、C 1-C 6烷基和C 1-C 6烷氧基；
n选自0、1和2。
在一些实施方案中，环B选自任选被R 1取代的8元含氮杂环烷基，所述含氮杂环烷基呈桥环形式。
在一些实施方案中，环B选自任选被R 1取代的以下基团：
Figure PCTCN2022122041-appb-000003
在一些实施方案中，环B选自任选被R 1取代的以下基团：
Figure PCTCN2022122041-appb-000004
在一些实施方案中，R 1选自卤素、OH、C 1-C 3烷基、C 1-C 3烷氧基、HC(＝O)-、-CO 2R 1a、-CON(R 1a) 2和5-6元杂芳基，所述C 1-C 3烷基、C 1-C 3烷氧基或5-6元杂芳基任选被R 1b取代。
在一些实施方案中，R 1a选自H和C 1-C 3烷基。
在一些实施方案中，R 1选自卤素、OH、C 1-C 3烷基和C 1-C 3烷氧基，所述C 1-C 3烷基或C 1-C 3烷氧基任选被R 1b取代。
在一些实施方案中，R 1b选自氘、卤素、OH、CN和NH 2。
在一些实施方案中，R 1b选自卤素、OH和CN。
在一些实施方案中，R 1选自卤素、OH、甲基、甲氧基、CN、CNCH 2-、CNCH 2CH 2-和羟甲基。
在一些实施方案中，环B选自
Figure PCTCN2022122041-appb-000005
在一些实施方案中，环A选自任选被R 4取代的如下基团：5-6元杂芳环、苯环、四氢吡啶环、二氢吡喃环、环己烯和环己二烯。
在一些实施方案中，环A选自苯环、6元杂芳环、6元杂环和C 6环烯环，所述苯环、6元杂芳环、6元杂环或C 6环烯环任选被R 4取代。
在一些实施方案中，环A选自任选被R 4取代的如下基团：
Figure PCTCN2022122041-appb-000006
Figure PCTCN2022122041-appb-000007
在一些实施方案中，环A选自任选被R 4取代的如下基团：
Figure PCTCN2022122041-appb-000008
Figure PCTCN2022122041-appb-000009
在一些实施方案中，环A选自任选被R 4取代的如下基团：
Figure PCTCN2022122041-appb-000010
在一些实施方案中，环A选自任选被R 4取代的
Figure PCTCN2022122041-appb-000011
在一些实施方案中，R 4选自卤素、OH、＝O、C 1-C 6烷基和C 1-C 6烷氧基，所述C 1-C 6烷基或C 1-C 6烷氧基任选被R 4a取代。
在一些实施方案中，R 4选自卤素、＝O和任选被R 4a取代的C 1-C 6烷基。
在一些实施方案中，R 4a选自卤素、OH和CN。
在一些实施方案中，R 4选自F、Cl和甲基。
在一些实施方案中，L选自O和键。
在一些实施方案中，L选自键。
在一些实施方案中，L为O。
在一些实施方案中，R 3选自萘基、苯基和5-10元杂芳基，所述萘基、苯基或5-10元杂芳基任选被R 3a取代。
在一些实施方案中，R 3选自萘基、苯基、吡啶基、苯并吡咯基、苯并吡唑基、苯并噻吩基、苯并噻唑基、喹啉基、异喹啉基、苯并异噻唑基、苯并咪唑基和苯并呋喃基，所述萘基、苯基、吡啶基、苯并吡咯基、苯并吡唑基、苯并噻吩基、苯并噻唑基、喹啉基、异喹啉基、苯并异噻唑基、苯并咪唑基或苯并呋喃基任选被R 3a取代。
在一些实施方案中，R 3选自萘基、苯基、吡啶基、苯并噻吩基和苯并吡唑基，所述萘基、苯基、吡啶基、苯并噻吩基或苯并吡唑基任选被R 3a取代。
在一些实施方案中，R 3a选自卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、-CH 2C(＝O)N(R 3b) 2、-(C 2-C 4亚炔基)-N(R 3b) 2、N(R 3b) 2、C 3-C 6环烷基和5-6元杂芳基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、C 2-C 4亚炔基、C 3-C 6环烷基或5-6元杂芳基任选被R 3c取代；或者两个R 3a与其各自相连的原子一起形成C 4-C 6环烯基或5-7元杂环基，所述C 4-C 6环烯基或5-7元杂环基任选被R 3d取代。
在一些实施方案中，R 3a选自卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、-CH 2C(＝O)N(R 3b) 2、-(C 2-C 4亚炔基)-N(R 3b) 2、N(R 3b) 2、C 3-C 6环烷基和5-6元杂芳基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、C 2-C 4亚炔基、C 3-C 6环烷基或5-6元杂芳基任选被R 3c取代。
在一些实施方案中，R 3b选自H和C 1-C 3烷基。
在一些实施方案中，R 3c选自氘、卤素、OH、CN、NH 2和C 1-C 3烷氧基。
在一些实施方案中，R 3c选自F。
在一些实施方案中，R 3d选自卤素、OH、C 1-C 3烷基和C 1-C 3烷氧基。
在一些实施方案中，R 3a选自卤素、OH、CN、CF 3、CHF 2、甲基、羟甲基、-CH 2OCH 3、乙基、羟乙基、2,2,2-三氟乙基、2,2-二氟乙基、2-氟乙基、正丙基、异丙基、1-羟基-1-甲基 乙基、1-F-1-甲基乙基、3-氟丙基、异丁基、-C(CH 3)CH 2CH 3、甲氧基、二氟甲氧基、三氟甲氧基、异丙氧基、甲硫基、三氟甲硫基、CNCH 2CH 2-、NH 2、NHCH 3、N(CH 3) 2、NHCH 2CH 3、乙炔基、-C≡C-CH 2OH、-C≡C-CH 2NH 2、-C≡C-CH 2D、-CH 2C≡CH、-C≡C-CH 3、-C≡C-CH 2CH 3、-CH 2C(＝O)NH 2、环丙基、1-甲基环丙基、2-氟环丙基、2-甲基环丙基、环丁基和三唑基，或者两个R 3a与其各自相连的原子一起形成环己烯基、环戊烯基或
Figure PCTCN2022122041-appb-000012
所述环己烯基、环戊烯基或
Figure PCTCN2022122041-appb-000013
任选被甲基、OH或卤素取代。
在一些实施方案中，R 3a选自F、Cl、OH、乙炔基、CF 3、甲基、乙基、NH 2和CN。
在一些实施方案中，R 3选自
Figure PCTCN2022122041-appb-000014
Figure PCTCN2022122041-appb-000015
在一些实施方案中，R 3-L-选自
Figure PCTCN2022122041-appb-000016
Figure PCTCN2022122041-appb-000017
在一些实施方案中，R 5选自H、OH、CN、C 2-C 4炔基、C 1-C 3卤代烷基和C 3-C 6环烷基。
在一些实施方案中，R 5选自H、CN、C 2-C 4炔基和C 1-C 3卤代烷基。
在一些实施方案中，R 5选自H、CN和-C≡CH。
在一些实施方案中，W为O或NH。
在一些实施方案中，W为O。
在一些实施方案中，n为1。
在一些实施方案中，R 2选自任选被R 7取代的以下基团：
Figure PCTCN2022122041-appb-000018
在一些实施方案中，R 2选自任选被R 7取代的
Figure PCTCN2022122041-appb-000019
在一些实施方案中，R 2选自任选被R 7取代的
Figure PCTCN2022122041-appb-000020
在一些实施方案中，R 7选自卤素、OH、CN、C 1-C 6烷基和C 1-C 6烷氧基，所述C 1-C 6烷基或C 1-C 6烷氧基任选被R 7a取代。
在一些实施方案中，R 7a选自氘、卤素、OH、CN和NH 2。
在一些实施方案中，R 7选自卤素和卤代C 1-C 6烷基。
在一些实施方案中，R 7选自F。
在一些实施方案中，R 2选自
Figure PCTCN2022122041-appb-000021
Figure PCTCN2022122041-appb-000022
在一些实施方案中，W-(CH 2) n-R 2选自
Figure PCTCN2022122041-appb-000023
Figure PCTCN2022122041-appb-000024
在一些实施方案中，本发明的式(I)化合物选自式(IIa)化合物：
Figure PCTCN2022122041-appb-000025
其中，作为环A的
Figure PCTCN2022122041-appb-000026
还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如式(I)中所定义。
在一些实施方案中，本发明的式(I)化合物选自式(IIb)化合物：
Figure PCTCN2022122041-appb-000027
其中，
Figure PCTCN2022122041-appb-000028
代表单键或双键，作为环A的
Figure PCTCN2022122041-appb-000029
还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如式(I)中所定义。
在一些实施方案中，本发明的式(I)化合物选自式(IIc)化合物：
Figure PCTCN2022122041-appb-000030
其中，作为环A的
Figure PCTCN2022122041-appb-000031
还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如式(I)中所定义。
在一些实施方案中，本发明的式(I)化合物选自以下化合物：
Figure PCTCN2022122041-appb-000032
Figure PCTCN2022122041-appb-000033
Figure PCTCN2022122041-appb-000034
Figure PCTCN2022122041-appb-000035
Figure PCTCN2022122041-appb-000036
Figure PCTCN2022122041-appb-000037
Figure PCTCN2022122041-appb-000038
Figure PCTCN2022122041-appb-000039
Figure PCTCN2022122041-appb-000040
Figure PCTCN2022122041-appb-000041
Figure PCTCN2022122041-appb-000042
Figure PCTCN2022122041-appb-000043
Figure PCTCN2022122041-appb-000044
Figure PCTCN2022122041-appb-000045
Figure PCTCN2022122041-appb-000046
Figure PCTCN2022122041-appb-000047
Figure PCTCN2022122041-appb-000048
Figure PCTCN2022122041-appb-000049
另一方面，本发明提供药物组合物，其包含本发明的式(I)化合物或其立体异构体或其药学上可接受的盐和药学上可接受的辅料。
另一方面，本发明提供治疗哺乳动物中与KRAS G12D突变相关的疾病或病症的方法，包括对需要该治疗的哺乳动物，优选人类，给予治疗有效量的式(I)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物。
另一方面，本发明提供治疗哺乳动物的肿瘤的方法，包括对需要该治疗的哺乳动物，优选人类，给予治疗有效量的式(I)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物。
另一方面，本发明提供式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物在制备预防或者治疗与KRAS G12D突变相关的疾病的药物中的用途。
另一方面，本发明提供式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物在制备预防或者治疗肿瘤的药物中的用途。
另一方面，本发明提供式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物在预防或者治疗与KRAS G12D突变相关的疾病中的用途。
另一方面，本发明提供式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物在预防或者治疗肿瘤方面的用途。
另一方面，本发明提供预防或者治疗与KRAS G12D突变相关的疾病的式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物。
另一方面，本发明提供预防或者治疗肿瘤的式(Ⅰ)化合物或其立体异构体或其药学上可接受的盐、或其药物组合物。
在一些实施方案中，与KRAS G12D突变相关的疾病选自肿瘤。
在一些实施方案中，所述肿瘤选自癌症。
在一些实施方案中，所述癌症选自胃癌。
术语定义和说明
除非另有说明，本发明中所用的术语具有下列含义，本发明中记载的基团和术语定义，包括其作为实例的定义、示例性的定义、优选的定义、表格中记载的定义、实施例中具体化合物的定义等，可以彼此之间任意组合和结合。一个特定的术语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照本领域普通的含义去理解。当本文中出现商品名时，意在指代其对应的商品或其活性成分。
本文中
Figure PCTCN2022122041-appb-000050
表示连接位点。
本文中，由实线和虚线描绘的键
Figure PCTCN2022122041-appb-000051
表示单键或双键。
本文中消旋体或者对映体纯的化合物的图示法来自Maehr，J.Chem.Ed.1985，62:114-120。除非另有说明，用楔形键和虚楔键
Figure PCTCN2022122041-appb-000052
表示一个立体中心的绝对构型，用黑实键和虚键
Figure PCTCN2022122041-appb-000053
表示一个立体中心的相对构型(如脂环化合物的顺反构型)。
术语“互变异构体”是指因分子中某一原子在两个位置迅速移动而产生的官能团异构体。本发明化合物可表现出互变异构现象。互变异构的化合物可以存在两种或多种可相互转化的种类。互变异构体一般以平衡形式存在，尝试分离单一互变异构体时通常产生一种混合物，其理化性质与化合物的混合物是一致的。平衡的位置取决于分子内的化学特性。例如，在很多脂族醛和酮如乙醛中，酮型占优势；而在酚中，烯醇型占优势。本发明包含化合物的所有互变异构形式。
术语“立体异构体”是指由分子中原子在空间上排列方式不同所产生的异构体，包括顺反异构体、对映异构体和非对映异构体。
本发明的化合物可以具有不对称原子如碳原子、硫原子、氮原子、磷原子或不对称双键，因此本发明的化合物可以存在特定的几何或立体异构体形式。特定的几何或立体异构体形式可以是顺式和反式异构体、E型和Z型几何异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，以及其外消旋混合物或其它混合物，例如对映异构体或非对映体富集的混合物，以上所有这些异构体以及它们的混合物都属于本发明化合物的定义范围之内。烷基等取代基中可存在另外的不对称碳原子、不对称硫原子、不对称氮原子或不对称磷原子，所有取代基中涉及到的这些异构体以及它们的混合物，也均包括在本发明化合物的定义范围之内。本发明的含有不对称原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来，光学活性纯的形式可以从外消旋混合物拆分，或通过使用手性原料或手性试剂合成。
术语“被取代”是指特定原子上的任意一个或多个氢原子被取代基取代，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧代(即＝O)时，意味着两个氢原子被取代，氧代不会发生在芳香基上。
术语“任选”或“任选地”是指随后描述的事件或情况可以发生或不发生，该描述包括发生所述事件或情况和不发生所述事件或情况。例如，乙基“任选”被卤素取代，是指乙基可以是 未被取代的(CH 2CH 3)、单取代的(CH 2CH 2F、CH 2CH 2Cl等)、多取代的(CHFCH 2F、CH 2CHF 2、CHFCH 2Cl、CH 2CHCl 2等)或完全被取代的(CF 2CF 3、CF 2CCl 3、CCl 2CCl 3等)。本领域技术人员可理解，对于包含一个或多个取代基的任何基团，不会引入任何在空间上不可能存在和/或不能合成的取代或取代模式。
当任何变量(例如R 1、R 4)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。例如，如果一个基团被2个R 4所取代，则每个R 4都有独立的选项。
当一个连接基团的数量为0时，比如-(CH 2) 0-，表示该连接基团为键。
当其中一个变量选自化学键或不存在时，表示其连接的两个基团直接相连，比如A-L-R 3中L代表键时表示该结构实际上是A-R 3。
当本文中涉及到的连接基团若没有指明其连接方向，则其连接方向是任意的。例如当结构单元
Figure PCTCN2022122041-appb-000054
中的环A选自
Figure PCTCN2022122041-appb-000055
时，此时结构单元
Figure PCTCN2022122041-appb-000056
既可以为
Figure PCTCN2022122041-appb-000057
也可以为
Figure PCTCN2022122041-appb-000058
本文中的C m-C n是指具有m-n范围中的整数个碳原子。例如“C 1-C 6”是指该基团可具有1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子或6个碳原子。
术语“烷基”是指通式为C nH 2n+1的烃基，该烷基可以是直链或支链的。术语“C 1-C 6烷基”应理解为表示具有1、2、3、4、5或6个碳原子的直链或支链饱和一价烃基。所述烷基的具体实例包括但不限于甲基、乙基、丙基、丁基、戊基、己基、异丙基、异丁基、仲丁基、叔丁基、异戊基、2-甲基丁基、1-甲基丁基、1-乙基丙基、1,2-二甲基丙基、新戊基、1,1-二甲基丙基、4-甲基戊基、3-甲基戊基、2-甲基戊基、1-甲基戊基、2-乙基丁基、1-乙基丁基、3,3-二甲基丁基、2,2-二甲基丁基、1,1-二甲基丁基、2,3-二甲基丁基、1,3-二甲基丁基或1,2-二甲基丁基等。术语“C 1-C 3烷基”可理解为表示具有1至3个碳原子的直链或支链饱和一价烃基。所述“C 1-C 6烷基”可以包含“C 1-C 3烷基”。
术语“卤代烷基”是指所述烷基中的任意一个或多个氢原子被卤素原子所取代而产生的基团。在多个氢原子被取代的情况下，每个用于取代的卤素原子彼此独立选择。“C 1-C 3卤代烷基”是指“C 1-C 3烷基”中的任意一个或多个氢原子被卤素原子所取代而产生的基团。
术语“烷氧基”是指直链或支链醇类失去羟基上的氢原子产生的一价基团，可理解为“烷基氧基”或“烷基-O-”。术语“C 1-C 6烷氧基”可理解为“C 1-C 6烷基氧基”或“C 1-C 6烷基-O-”；术语“C 1-C 3烷氧基”可理解为“C 1-C 3烷基氧基”或“C 1-C 3烷基-O-”。所述“C 1-C 6烷氧基”可以进一步包含“C 1-C 3烷氧基”。
术语“卤代烷氧基”是指所述烷氧基中的任意一个或多个氢原子被卤素原子所取代而产生的基团。在多个氢原子被取代的情况下，每个用于取代的卤素原子彼此独立选择。“C 1-C 3卤代烷氧基”是指“C 1-C 3烷氧基”中的任意一个或多个氢原子被卤素原子所取代而产生的基团。
术语“烯基”是指由碳原子和氢原子组成的直链或支链的且具有至少一个双键的一价不饱和脂肪族烃基。术语“C 2-C 4烯基”应理解为表示直链或支链的不饱和一价烃基，其包含一个或多个双键并且具有2、3或4个碳原子，“C 2-C 4烯基”优选C 2或C 3烯基。应理解，在所述烯基包含多于一个双键的情况下，所述双键可相互分离或共轭。所述烯基的具体实例包括但不限于乙烯基、烯丙基、(E)-2-甲基乙烯基、(Z)-2-甲基乙烯基、(E)-丁-2-烯基、(Z)-丁-2-烯基、(E)-丁-1-烯基、(Z)-丁-1-烯基、异丙烯基、2-甲基丙-2-烯基、1-甲基丙-2-烯基、2-甲基丙-1-烯基、(E)-1-甲基丙-1-烯基或(Z)-1-甲基丙-1-烯基等。
术语“炔基”是指由碳原子和氢原子组成的直链或支链的具有至少一个三键的一价不饱和脂肪族烃基。术语“C 2-C 4炔基”可理解为表示直链或支链的不饱和一价烃基，其包含一个或多 个三键并且具有2、3或4个碳原子。“C 2-C 4炔基”的实例包括但不限于乙炔基(-C≡CH)、丙炔基(-C≡CCH 3、-CH 2C≡CH)、丁-1-炔基、丁-2-炔基或丁-3-炔基。“C 2-C 4炔基”可以包含“C 2-C 3炔基”，“C 2-C 3炔基”实例包括乙炔基(-C≡CH)、丙-1-炔基(-C≡CCH 3)、丙-2-炔基(炔丙基)。
术语“亚炔基”是指从所述“炔基”中再移除一个氢原子而得到的二价基团。“C 2-C 4亚炔基”是指从所述“C 2-C 4炔基”中再移除一个氢原子而得到的二价基团，其实例包括但不限于-C≡C-、-C≡C-CH 2-等。
术语“环烷基”是指完全饱和的且以单环、并环、桥环或螺环等形式存在的碳环。除非另有指示，该碳环通常为3至10元环。术语“C 3-C 10环烷基”应理解为表示饱和的一价单环、并环、螺环或桥环，其具有3、4、5、6、7、8、9或10个碳原子。所述环烷基的具体实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基、环癸基，降冰片基(双环[2.2.1]庚基)、双环[2.2.2]辛基、金刚烷基、螺[4.5]癸烷基等。术语“C 3-C 10环烷基”可以包含“C 3-C 6环烷基”，术语“C 3-C 6环烷基”可理解为表示饱和的一价单环或双环烃环，其具有3、4、5或6个碳原子，具体实例包括但不限于环丙基、环丁基、环戊基或环己基等。
术语“环烷基氧基”可理解为“环烷基-O-”。术语“C 3-C 10环烷氧基”可以包含“C 3-C 6环烷基氧基”。
术语“环烯基”是指含有至少一个碳-碳双键的非芳族单环或多环烃基。“C 3-C 6环烯基”是指具有3、4、5或6个碳原子作为环原子且包含至少一个碳-碳双键的非芳族环状烃。C 3-C 6环烯基的具体实例包括但不限于环丙烯基、环丁烯基、环戊烯基、环戊二烯基、环己烯基、环己二烯基等。术语“C 3-C 6环烯基”可以包含“C 4-C 6环烯基”，“C 4-C 6环烯基”可以进一步包含“C 6环烯基”。
术语“杂环基”是指完全饱和的或部分饱和的(整体上不是具有芳香性的杂芳族)一价单环、并环、螺环或桥环基团，其环原子中含有1-5个杂原子或杂原子团(即含有杂原子的原子团)，所述“杂原子或杂原子团”包括但不限于氮原子(N)、氧原子(O)、硫原子(S)、磷原子(P)、硼原子(B)、-S(＝O) 2-、-S(＝O)-以及任选被取代的-NH-、-S(＝O)(＝NH)-、-C(＝O)NH-、-C(＝NH)-、-S(＝O) 2NH-、S(＝O)NH-或-NHC(＝O)NH-等。术语“4-10元杂环基”是指环原子数目为4、5、6、7、8、9或10的杂环基，且其环原子中含有1-5个独立选自上文所述的杂原子或杂原子团。“4-10元杂环基”包括“8-10元杂环基”，“8-10元杂环基”进一步包含“4-7元杂环基”，“4-7元杂环基”更进一步包含“5-7元杂环基”，“5-7元杂环基”更进一步包含6元杂环基。其中，4元杂环基的具体实例包括但不限于氮杂环丁烷基或氧杂环丁烷基；5元杂环基的具体实例包括但不限于四氢呋喃基、二氧杂环戊烯基、吡咯烷基、咪唑烷基、吡唑烷基、吡咯啉基、4,5-二氢噁唑基或2,5-二氢-1H-吡咯基；6元杂环基的具体实例包括但不限于四氢吡喃基、哌啶基、吗啉基、二噻烷基、硫代吗啉基、哌嗪基、三噻烷基、四氢吡啶基或4H-[1,3,4]噻二嗪基；7元杂环基的具体实例包括但不限于二氮杂环庚烷基。所述杂环基还可以是双环基，其中，5,5元双环基的具体实例包括但不限于六氢环戊并[c]吡咯-2(1H)-基；5,6元双环基的具体实例包括但不限于六氢吡咯并[1,2-a]吡嗪-2(1H)-基、5,6,7,8-四氢-[1,2,4]三唑并[4,3-a]吡嗪基或5,6,7,8-四氢咪唑并[1,5-a]吡嗪基。任选地，所述杂环基可以是上述4-7元杂环基的苯并稠合环基，具体实例包括但不限于二氢异喹啉基等。“4-7元杂环基”进一步可以包含“4-6元杂环基”、“5-6元杂环基”、“4-7元杂环烷基”、“4-6元杂环烷基”、“5-6元杂环烷基”等范围。本发明中尽管有些双环类杂环基部分地含有一个苯环或一个杂芳环，但所述杂环基整体上仍是无芳香性的。
术语“含氮杂环基”是指至少含一个氮原子作为环原子的“杂环基”。
术语“杂环烷基”是指完全饱和的且以单环、并环、桥环或螺环等形式存在的一价环状基团，其环的环原子中含有1-5个杂原子或杂原子团(即含有杂原子的原子团)，所述“杂原子或杂原子团”包括但不限于氮原子(N)、氧原子(O)、硫原子(S)、磷原子(P)、硼原子(B)、-S(＝O) 2-、-S(＝O)-以及任选被取代的-NH-、-S(＝O)(＝NH)-、-C(＝O)NH-、-C(＝NH)-、-S(＝O) 2NH-、S(＝O)NH-或-NHC(＝O)NH-等。术语“4-10元杂环烷基”是指环原子数目为4、5、6、7、8、9或10的杂 环烷基，且其环原子中含有1-5个独立选自上文所述的杂原子或杂原子团。“4-10元杂环烷基”包括“8-10元杂环烷基”。
术语“含氮杂环烷基氧基”是指至少含一个氮原子作为环原子的“杂环烷基”。
术语“芳基”是指具有共轭的π电子体系的全碳单环或稠合多环的芳香环基团。芳基可以具有6-14个碳原子或6-10个碳原子。术语“C 6-C 14芳基”应理解为具有6～14个碳原子的一价芳香性的单环、双环或三环烃环。特别是具有6个碳原子的环(“C 6芳基”)，例如苯基；或者具有9个碳原子的环(“C 9芳基”)，例如茚基；或者具有10个碳原子的环(“C 10芳基”)，例如萘基；或者具有13个碳原子的环(“C 13芳基”)，例如芴基；或者是具有14个碳原子的环(“C 14芳基”)，例如蒽基。术语“C 6-C 10芳基”应理解为具有6～10个碳原子的一价芳香性或部分芳香性的全碳单环或双环基团。术语“C 6-C 14芳基”可以包含“C 6-C 10芳基”。
术语“杂芳基”是指具有芳香性的单环或稠合多环体系，其中含有至少一个选自N、O、S的环原子，其余环原子为C的芳香环基。术语“5-14元杂芳基”应理解为包括这样的一价单环或双环芳族环系：其具有5、6、7、8、9、10、11、12、13或14个环原子，特别是5或6或9或10个环原子，且其包含1-5个，优选1-3个独立选自N、O和S的杂原子。特别地，杂芳基选自噻吩基、呋喃基、吡咯基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、噁二唑基、三唑基或噻二唑基等以及它们的苯并衍生物，例如苯并呋喃基、苯并噻吩基、苯并噻唑基、苯并噁唑基、苯并异噁唑基、苯并咪唑基、苯并三唑基、吲唑基、吲哚基或异吲哚基等；或吡啶基、哒嗪基、嘧啶基、吡嗪基或三嗪基等以及它们的苯并衍生物，例如喹啉基、喹唑啉基或异喹啉基等；或吖辛因基、吲嗪基、嘌呤基等以及它们的苯并衍生物；或噌啉基、酞嗪基、喹唑啉基、喹喔啉基、萘啶基、蝶啶基、咔唑基、吖啶基、吩嗪基、吩噻嗪基或吩噁嗪基等。术语“5-6元杂芳基”指具有5或6个环原子的芳族环系，且其包含1-3个，优选1-2个独立选自N、O和S的杂原子。术语“5-14元杂芳基”可以包含“5-10元杂芳基”，“5-10元杂芳基”可以进一步包含“5-6元杂芳基”，“5-6元杂芳基”可以更进一步包含“6元杂芳基”。
术语“卤”或“卤素”是指氟、氯、溴或碘。
术语“羟基”是指-OH基团。
术语“氰基”是指-CN基团。
术语“巯基”是指-SH基团。
术语“氨基”是指-NH 2基团。
术语“硝基”是指-NO 2基团。
术语“治疗有效量”意指(i)治疗或预防特定疾病、病况或障碍，(ii)减轻、改善或消除特定疾病、病况或障碍的一种或多种症状，或(iii)预防或延迟本文中所述的特定疾病、病况或障碍的一种或多种症状发作的本发明化合物的用量。构成“治疗有效量”的本发明化合物的量取决于该化合物、疾病状态及其严重性、给药方式以及待被治疗的哺乳动物的年龄而改变，但可例行性地由本领域技术人员根据其自身的知识及本公开内容而确定。
术语“药学上可接受的”，是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。
术语“药学上可接受的盐”是指药学上可接受的酸或碱的盐，包括化合物与无机酸或有机酸形成的盐，以及化合物与无机碱或有机碱形成的盐。
术语“药物组合物”是指一种或多种本发明的化合物或其盐与药学上可接受的辅料组成的混合物。药物组合物的目的是有利于对有机体给予本发明的化合物。
术语“药学上可接受的辅料”是指对有机体无明显刺激作用，而且不会损害该活性化合物的生物活性及性能的那些辅料。合适的辅料是本领域技术人员熟知的，例如碳水化合物、蜡、水溶性和/或水可膨胀的聚合物、亲水性或疏水性材料、明胶、油、溶剂、水等。
词语“包括(comprise)”或“包含(comprise)”及其英文变体例如comprises或comprising 应理解为开放的、非排他性的意义，即“包括但不限于”。
本发明还包括与本文中记载的那些相同的，但一个或多个原子被原子量或质量数不同于自然中通常发现的原子量或质量数的原子置换的同位素标记的本发明化合物。可结合到本发明化合物的同位素的实例包括氢、碳、氮、氧、磷、硫、氟、碘和氯的同位素，诸如分别为 2H、 3H、 11C、 13C、 14C、 13N、 15N、 15O、 17O、 18O、 31P、 32P、 35S、 18F、 123I、 125I和 36Cl等。
某些同位素标记的本发明化合物(例如用 3H及 14C标记)可用于化合物和/或底物组织分布分析中。氚化(即 3H)和碳-14(即 14C)同位素对于由于它们易于制备和可检测性是尤其优选的。正电子发射同位素，诸如 15O、 13N、 11C和 18F可用于正电子发射断层扫描(PET)研究以测定底物占有率。通常可以通过与公开于下文的方案和/或实施例中的那些类似的下列程序，通过同位素标记试剂取代未经同位素标记的试剂来制备同位素标记的本发明化合物。
本发明的药物组合物可通过将本发明的化合物与适宜的药学上可接受的辅料组合而制备，例如可配制成固态、半固态、液态或气态制剂，如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等。
给予本发明化合物或其药学上可接受的盐或其药物组合物的典型途径包括但不限于口服、直肠、局部、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。
本发明的药物组合物可以采用本领域众所周知的方法制造，如常规的混合法、溶解法、制粒法、乳化法、冷冻干燥法等。
在一些实施方案中，药物组合物是口服形式。对于口服给药，可以通过将活性化合物与本领域熟知的药学上可接受的辅料混合，来配制该药物组合物。这些辅料能使本发明的化合物被配制成片剂、丸剂、锭剂、糖衣剂、胶囊剂、液体、凝胶剂、浆剂、悬浮剂等，用于对患者的口服给药。
可以通过常规的混合、填充或压片方法来制备固体口服组合物。例如，可通过下述方法获得：将所述的活性化合物与固体辅料混合，任选地碾磨所得的混合物，如果需要则加入其它合适的辅料，然后将该混合物加工成颗粒，得到了片剂或糖衣剂的核心。适合的辅料包括但不限于：粘合剂、稀释剂、崩解剂、润滑剂、助流剂或矫味剂等。
药物组合物还可适用于肠胃外给药，如合适的单位剂型的无菌溶液剂、混悬剂或冻干产品。
本文所述的通式(Ⅰ)化合物的所有施用方法中，每天给药的剂量为0.01mg/kg到200mg/kg体重，优选为0.05mg/kg到50mg/kg体重，更优选0.1mg/kg到30mg/kg体重，以单独或分开剂量的形式。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其它化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
本发明具体实施方式的化学反应是在合适的溶剂中完成的，所述的溶剂须适合于本发明的化学变化及其所需的试剂和物料。为了获得本发明的化合物，有时需要本领域技术人员在已有实施方式的基础上对合成步骤或者反应流程进行修改或选择。
在一些实施方案中，本发明通式(I)的部分化合物可以由有机合成领域技术人员通过以下合成路线1或合成路线2来制备：
Figure PCTCN2022122041-appb-000059
合成路线1
Figure PCTCN2022122041-appb-000060
合成路线2
其中X 1选自CH、CR 4或N，X 2选自卤素，环B、L、R 3、R 4、W、R 2和n如式(I)中所定义；
在合成路线1和合成路线2中，式(I-1)所示的化合物经取代反应化得到式(I-2)所示化合物；式(I-2)所示化合物在碱性条件下，在催化剂存在下经插羰偶联反应，得到式(I-3)所示化合物；式(I-3)所示化合物和式(I-4)所示化合物先在四氢呋喃下反应后加入氨水甲醇溶液，经环化反应得到式(I-5)所示化合物；式(I-5)所示化合物在三氯氧磷条件下经取代反应得到式(I-6)所示化合物；式(I-6)所示化合物在碱性条件下经取代反应得到式(I-7)所示化合物；式(I-7)所示化合物在碱性条件下经取代反应得到式(I-8)所示化合物；式(I-8)所示化合物和式(I-9)所示化合物在碱性条件下，在催化剂存在下经C-C偶联反应得到式(I)所示化合物。
在一些实施方案中，本发明通式(I)的部分化合物可以由有机合成领域技术人员通过以下合成路线3来制备：
Figure PCTCN2022122041-appb-000061
合成路线3
其中R 4、L、R 3、环B、W、R 2和n如式(I)中所定义；
在合成路线3中，式(II-1)和式(I-9)所示化合物在碱性条件下，在催化剂存在下经C-C偶联反应得到式(II-2)所示化合物；式(II-2)所示化合物和式(II-3)所示化合物在碱性条件下，经取代反应得到式(II-4)所示化合物；式(II-4)所示化合物和式(II-5)所示化合物在碱性条件下，经环化反应得到式(II-6)所示化合物；式(II-6)所示化合物可按照第①种路径先在三氯氧磷条件下经取代反应得到式(II-7)所示化合物，然后式(II-7)所示化合物在碱性条件下经取代反应得到式(II-8)所示化合物；或者式(II-6)所示化合物可按照第②种路径在碱性条件下，在催化剂存在下经取代反应直接得到式(II-8)所示化合物；式(II-8)所示化合物在氧化条件下，经氧化反应得到式(II-9)所示化合物；式(II-9)所示化合物在碱性条件下，经取代反应得到式(I)所示化合物。
具体实施方式
下面通过实施例对发明进行详细描述，但并不意味着对本发明的任何不利限制。本文已经详细地描述了本发明，其中也公开了其具体实施方式，对本领域的技术人员而言，在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行的各种改变和改进将是显而易见的。本发明所使用的所有试剂是市售的，无需进一步纯化即可使用。
除非另作说明，混合溶剂表示的比例是体积混合比例。除非另作说明，否则，％是指wt％。
化合物经手工或
Figure PCTCN2022122041-appb-000062
软件命名，市售化合物采用供应商目录名称。
化合物的结构是通过核磁共振(NMR)和/或质谱(MS)来确定的。NMR位移的单位为10 -6(ppm)。NMR测定的溶剂为氘代二甲基亚砜、氘代氯仿、氘代甲醇等，内标为四甲基硅烷(TMS)；“IC 50”指半数抑制浓度，指达到最大抑制效果一半时的浓度。
术语或缩写说明：
DIEA：N,N-二异丙基乙胺；Boc：叔丁氧羰基；TIPS：三异丙基甲硅烷基；TBAF：四丁基氟化铵；1,4-dioxane：Pd(dppf)Cl 2：[1,1'-双(二苯基膦)二茂铁]二氯化钯；M：摩尔/升。
下文的洗脱剂可由两种或多种溶剂形成混合洗脱剂，其比值为各溶剂的体积比，如“0～10％甲醇/二氯甲烷”表示梯度洗脱过程中，混合洗脱剂中的甲醇与二氯甲烷的体积用量比为0:100～10:100。
实施例1：4-(4-(3,8-二氮杂二环[3.2.1]辛-3-基)-8-氟-2-((八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-基)甲氧基)吡啶并[4,3-d]嘧啶-7-基)-5-乙炔基-6-氟萘-2-酚(化合物1)的制备
Figure PCTCN2022122041-appb-000063
合成路线：
Figure PCTCN2022122041-appb-000064
步骤1：八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-羧酸盐酸盐(1b)的制备
室温下，将八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-甲腈(0.30g,1.9mmol,采用文献Crystal Growth&Design(2009),9(4),1786-1792公开的方法制备而得)溶于浓盐酸(5mL,w/w 37％)，100℃加热反应16小时。将反应液减压蒸馏除去溶剂，得到固体标题化合物1b(0.35g)。
步骤2：(八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-基)甲醇(1c)的制备
在0℃下将化合物1b(0.3g，1.4mmol)加入1M硼烷四氢呋喃溶液中(5mL)。0℃下搅拌1小时后加入甲醇(10mL)，室温反应16小时。将反应液浓缩，所得残余物经反相色谱法纯化(
Figure PCTCN2022122041-appb-000065
C 18快速硅胶柱，0.1％氨水：乙腈＝20：1～1：1洗脱)得固体标题化合物1c(0.12g)。
LC-MS:m/z(ESI):168[M+H] +。
步骤3：3-(7-氯-8-氟-2-((八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-基)甲氧基)吡啶并[4,3-d]嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛烷-8-羧酸叔丁酯(1e)的制备
将化合物1c(0.05g，0.3mmol)、化合物1d(0.08g，0.19mmol，采用专利WO2021/041671A1公开的中间体5的制备方法制得)和DIEA(0.085g,0.66mmol)溶于1,4-二氧六环(2mL)中，在100℃下加热反应16小时。将反应液浓缩，所得残余物经反相色谱法纯化(
Figure PCTCN2022122041-appb-000066
C 18快速硅胶柱，0.1％氨水：乙腈＝5：1～1：20洗脱)得固体标题化合物1e(0.065g)。
MS m/z(ESI):559[M+H] +。
步骤4：3-(8-氟-7-(7-氟-3-(甲氧基甲氧基)-8-((三异丙基甲硅烷基)乙炔基)萘-1-基)-2-((八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-基)甲氧基)吡啶并[4,3-d]嘧啶-4-基)-3,8-二氮杂二环[3.2.1]辛烷-8-羧酸叔丁酯(1g)的制备
氮气氛下，将1e(0.065g,0.12mmol)、1f(0.06g,0.12mmol,采用专利WO2021/041671A1 公开的中间体15的制备方法制得)、[1,1'-双(二苯基膦基)二茂铁]二氯化钯(0.008g，0.012mmol)、碳酸铯(0.095g,0.29mmol)、1,4-二氧六环(2mL)和水(0.5mL)的混合物在100℃下加热反应16小时。将反应液浓缩，所得残余物经反相色谱法纯化(
Figure PCTCN2022122041-appb-000067
C 18快速硅胶柱，0.1％氨水：乙腈＝1：1～1：20洗脱)得固体标题化合物1g(0.045g)。
MS m/z(ESI):909[M+H] +。
步骤5：4-(4-(3,8-二氮杂二环[3.2.1]辛烷-3-基)-8-氟-2-((八氢-2aH-吡咯并[2,1,5-cd]吡咯嗪-2a-基)甲氧基)吡啶并[4,3-d]嘧啶-7-基)-5-乙炔基-6-氟萘-2-酚(化合物1)的制备
将1g(0.04g,0.044mmol)溶于四丁基氟化铵的四氢呋喃溶液(1mol/L，2mL)中，在20℃下反应1小时。将反应液浓缩，所得残余物经反相色谱法纯化(0.1％氨水：乙腈＝4：1～1：20洗脱)，所得产物减压浓缩干燥后，再在0℃下加入氯化氢的1,4-二氧六环溶液(1mol/L,1mL)，0℃下反应3小时。再将反应液浓缩，所得残余物经反相色谱法纯化(
Figure PCTCN2022122041-appb-000068
C 18快速硅胶柱，0.1％氨水：乙腈＝4：1～1：4洗脱)得固体标题化合物1(0.008g)。
MS m/z(ESI):609[M+H] +；
1HNMR(400MHz,DMSO-d 6):δ10.16(s,1H),9.03(s,1H),7.97(dd,J＝9.1,5.9Hz,1H),7.46(t,J＝9.0Hz,1H),7.39(d,J＝2.5Hz,1H),7.17(d,J＝2.4Hz,1H),4.47(d,J＝11.1Hz,1H),4.31(d,J＝11.9Hz,1H),4.09(s,2H),3.93(s,1H),3.63(d,J＝12.1Hz,1H),3.59–3.50(m,3H),3.40–3.34(m,3H),1.93–1.82(m,2H),1.81–1.72(m,2H),1.71–1.62(m,7H),1.56–1.41(m,4H).
参考上述实施例的合成方法以及前述通用合成路线1、2和3，合成如下化合物，其结构和质谱数据为：
Figure PCTCN2022122041-appb-000069
Figure PCTCN2022122041-appb-000070
Figure PCTCN2022122041-appb-000071
Figure PCTCN2022122041-appb-000072
Figure PCTCN2022122041-appb-000073
Figure PCTCN2022122041-appb-000074
Figure PCTCN2022122041-appb-000075
Figure PCTCN2022122041-appb-000076
Figure PCTCN2022122041-appb-000077
Figure PCTCN2022122041-appb-000078
Figure PCTCN2022122041-appb-000079
Figure PCTCN2022122041-appb-000080
Figure PCTCN2022122041-appb-000081
Figure PCTCN2022122041-appb-000082
Figure PCTCN2022122041-appb-000083
Figure PCTCN2022122041-appb-000084
Figure PCTCN2022122041-appb-000085
Figure PCTCN2022122041-appb-000086
Figure PCTCN2022122041-appb-000087
生物学活性及相关性质测试例
测试例1、KRAS G12D抑制剂抑制AGS细胞增殖实验
1、实验仪器及材料
仪器名称 设备厂家 型号
全自动细胞计数仪 Beckman Vi-CELL XR
振荡器 Boxun BSD-YX3400
读板仪 PerkinElmer Envision
离心机 Eppendorf Eppendorf Mixmate
化合物稀释及加样仪 PerkinElmer Echo
细胞培养箱 THERMO THERMO Heracell VIOS 250i
AGS细胞 ATCC CRL-1739
实验所用细胞AGS为KRAS G12D突变的细胞株。细胞用Ham's F-12K(Kaighn's)培养基加10％FBS传代培养。液氮冻存细胞代数低的细胞。检测用试剂盒(
Figure PCTCN2022122041-appb-000088
3D Cell Viability Assay)通过对ATP进行定量测定来检测3D细胞微组织的活细胞数目的一种均质检测方法。试剂盒产生发光信号与存在的ATP量成正比，而ATP量直接与细胞数量成正比。
实验所需其它试剂及耗材信息如下：
Figure PCTCN2022122041-appb-000089
2、实验步骤
将培养的AGS细胞用PBS清洗一次后胰酶消化，收集离心，用培养液(Ham's  F-12K+10％FBS+1％Penicillin-Streptomycin)重悬计数后调整细胞浓度，将细胞种在384孔板上(200个细胞/20μl/孔)，37℃、5％CO 2细胞培养箱中培养过夜。待测化合物溶解于DMSO中，母液储存浓度为10mM。通过Echo仪器的dose-response程序进行化合物母液梯度稀释，稀释程序实验总体系50μL，起始浓度50μM，3倍稀释，10个浓度点，化合物和DMSO总体积为250nL。程序结束后，每个孔再补加30μL培养液，于离心机1000rpm离心5分钟后，继续在细胞培养箱培养7天。第7天后，将细胞板平衡至室温后每个孔加入25μL3D CTG试剂，震荡10分钟后再室温避光放置30分钟。化学发光信号使用Envision读板仪(发射波长400-700nm)测量每个孔中的Luminescence信号。100％抑制定义为10μM阳性化合物的处理下细胞的增殖抑制水平。阳性化合物为按照专利申请WO2021041671A1说明书实施例252所述方法制备得到的实施例252化合物。
3、数据分析
化合物对细胞增殖抑制率计算公式为：
细胞增殖抑制率％＝(Average_H–Sample)/(Average_H–L)x 100％
其中：
H＝Ave(Relative Signal_cell only DMSO)；
L＝Ave(Relative Signal_10μM positive compound)；
Sample指加药组各孔读取的信号值。
通过XLfit进行数据分析处理，浓度-效应曲线采用非线性四参数曲线拟合，并计算化合物的IC 50：
Y＝Bottom+(Top-Bottom)/(1+10^((LogIC 50-X)*HillSlope))
其中：
X:化合物浓度值的Log值；
Y:抑制百分比(抑制率％)；
Bottom为最小抑制百分比；
Top为最大抑制百分比；
HillSlope为曲线斜率系数。
本发明化合物对AGS细胞增殖抑制活性通过以上的试验进行测定，测得的IC 50值见表1。
表1
化合物编号 IC 50(nM)
1 164

Claims (16)

  1. 式(I)化合物或其立体异构体或其药学上可接受的盐：
    Figure PCTCN2022122041-appb-100001
    其中，
    环B选自任选被R 1取代的8-10元含氮杂环基，所述含氮杂环基呈桥环形式；
    R 1选自卤素、OH、＝O、CN、C 1-C 6烷基、C 1-C 6烷氧基、HC(＝O)-、-CO 2R 1a、-CON(R 1a) 2和5-6元杂芳基，其中所述C 1-C 6烷基、C 1-C 6烷氧基或5-6元杂芳基任选被R 1b取代；
    环A为5-6元杂芳基、苯基、4-7元杂环基或C 3-C 6环烯基，所述5-6元杂芳基、苯基、4-7元杂环基或C 3-C 6环烯基任选被R 4取代；
    R 4选自氘、卤素、OH、＝O、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基和C 3-C 10环烷基氧基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基或C 3-C 10环烷基氧基任选被R 4a取代；
    L选自O、-C(＝O)-和键；
    R 3选自C 6-C 14芳基和5-14元杂芳基，所述C 6-C 14芳基或5-14元杂芳基任选被R 3a取代；
    X选自CR 5和N；
    R 5选自H、卤素、OH、CN、NO 2、NH 2、NH(C 1-C 3烷基)、N(C 1-C 3烷基) 2、C 1-C 3烷基、C 1-C 3卤代烷基、C 1-C 3烷氧基、C 1-C 3卤代烷氧基、C 2-C 4炔基、C 3-C 10环烷基和C 3-C 10环烷基氧基；
    W选自O、NR 6和键；
    R 2选自
    Figure PCTCN2022122041-appb-100002
    所述R 2任选被R 7取代；
    R 7选自氘、卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基和C 3-C 10环烷基氧基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 3-C 10环烷基或C 3-C 10环烷基氧基任选被R 7a取代；
    R 3a选自卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4烯基、C 2-C 4炔基、-CH 2C(＝O)N(R 3b) 2、-(C 2-C 4亚炔基)-N(R 3b) 2、N(R 3b) 2、C 3-C 10环烷基和5-6元杂芳基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4烯基、C 2-C 4炔基、C 2-C 4亚炔基、C 3-C 10环烷基或5-6元杂芳基任选被R 3c取代；
    或者，两个R 3a与其各自相连的原子一起形成C 4-C 6环烯基或5-7元杂环基，所述C 4-C 6环烯基或5-7元杂环基任选被R 3d取代；
    R 1a、R 3b和R 6独立地选自H和C 1-C 6烷基；
    R 1b、R 3c、R 3d、R 4a和R 7a独立地选自氘、卤素、OH、CN、＝O、NH 2、C 1-C 6烷基和C 1-C 6烷氧基；
    n选自0、1和2。
  2. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，环B选自任选被R 1取代的以下基团：
    Figure PCTCN2022122041-appb-100003
  3. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，环A选自任选被R 4取代的如下基团：5-6元杂芳基、苯基、四氢吡啶基、二氢吡喃基、环己烯基和环己二烯基，优选选自任选被R 4取代的如下基团：
    Figure PCTCN2022122041-appb-100004
    Figure PCTCN2022122041-appb-100005
    进一步优选为任选被R 4取代的如下基团：
    Figure PCTCN2022122041-appb-100006
    Figure PCTCN2022122041-appb-100007
    更加优选为任选被R 4取代的
    Figure PCTCN2022122041-appb-100008
  4. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，R 4选自卤素、OH、＝O、C 1-C 6烷基和C 1-C 6烷氧基，所述C 1-C 6烷基或C 1-C 6烷氧基任选被R 4a取代。
  5. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，L选自O和键。
  6. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，R 3选自萘基、苯基和5-10元杂芳基，所述萘基、苯基或5-10元杂芳基任选被R 3a取代。
  7. 根据权利要求1或7所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，R 3a选自卤素、OH、CN、C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、-CH 2C(＝O)N(R 3b) 2、-(C 2-C 4亚炔基)-N(R 3b) 2、N(R 3b) 2、C 3-C 6环烷基和5-6元杂芳基，所述C 1-C 6烷基、C 1-C 6烷氧基、C 1-C 6烷硫基、C 2-C 4炔基、C 2-C 4亚炔基、C 3-C 6环烷基或5-6元杂芳基任选被R 3c取代；或者两个R 3a与其各自相连的原子一起形成C 4-C 6环烯基或5-7元杂环基，所述C 4-C 6环烯基或5-7元杂环基任选被R 3d取代。
  8. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，R 5选自H、CN、C 2-C 4炔基和C 1-C 3卤代烷基。
  9. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，W为O。
  10. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，R 2选自任选被R 7取代的以下基团：
    Figure PCTCN2022122041-appb-100009
  11. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中所述式(I)化合物选自式(IIa)化合物：
    Figure PCTCN2022122041-appb-100010
    其中，作为环A的
    Figure PCTCN2022122041-appb-100011
    还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如 权利要求1中所定义。
  12. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中所述式(I)化合物选自式(IIb)化合物：
    Figure PCTCN2022122041-appb-100012
    其中，
    Figure PCTCN2022122041-appb-100013
    代表单键或双键，作为环A的
    Figure PCTCN2022122041-appb-100014
    还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如权利要求1中所定义。
  13. 根据权利要求1所述的式(I)化合物或其药学上可接受的盐，其中所述式(I)化合物选自式(IIc)化合物：
    Figure PCTCN2022122041-appb-100015
    其中，作为环A的
    Figure PCTCN2022122041-appb-100016
    还任选被R 4取代，且环B、R 4、L、R 3、X、W、R 2和n如权利要求1中所定义。
  14. 根据权利要求1所述的式(I)化合物或其立体异构体或其药学上可接受的盐，其中，所述化合物具有选自如下之一的结构：
    Figure PCTCN2022122041-appb-100017
    Figure PCTCN2022122041-appb-100018
    Figure PCTCN2022122041-appb-100019
    Figure PCTCN2022122041-appb-100020
    Figure PCTCN2022122041-appb-100021
    Figure PCTCN2022122041-appb-100022
    Figure PCTCN2022122041-appb-100023
    Figure PCTCN2022122041-appb-100024
    Figure PCTCN2022122041-appb-100025
    Figure PCTCN2022122041-appb-100026
    Figure PCTCN2022122041-appb-100027
    Figure PCTCN2022122041-appb-100028
    Figure PCTCN2022122041-appb-100029
    Figure PCTCN2022122041-appb-100030
    Figure PCTCN2022122041-appb-100031
    Figure PCTCN2022122041-appb-100032
    Figure PCTCN2022122041-appb-100033
    Figure PCTCN2022122041-appb-100034
  15. 一种药物组合物，所述药物组合物包含权利要求1-14任一项所述的化合物或其药学上可接受的盐，以及药学上可接受的辅料。
  16. 权利要求1-14任一项所述的化合物或其药学上可接受的盐或者如权利要求15所述的药物组合物用于预防或治疗与KRAS G12D突变相关的疾病或病症的用途，所述与KRAS G12D突变相关的疾病或病症优选自肿瘤。
PCT/CN2022/122041 2021-09-29 2022-09-28 Kras g12d抑制剂化合物及其制备方法和应用 WO2023051586A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280065933.1A CN118043330A (zh) 2021-09-29 2022-09-28 Kras g12d抑制剂化合物及其制备方法和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111151279 2021-09-29
CN202111151279.X 2021-09-29

Publications (1)

Publication Number Publication Date
WO2023051586A1 true WO2023051586A1 (zh) 2023-04-06

Family

ID=85781325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/122041 WO2023051586A1 (zh) 2021-09-29 2022-09-28 Kras g12d抑制剂化合物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN118043330A (zh)
WO (1) WO2023051586A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198078A1 (zh) * 2022-04-11 2023-10-19 杭州英创医药科技有限公司 作为kras g12d抑制剂的多环化合物
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN111989321A (zh) * 2017-11-15 2020-11-24 米拉蒂治疗股份有限公司 Kras g12c抑制剂
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022187528A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline amine derivatives as kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111989321A (zh) * 2017-11-15 2020-11-24 米拉蒂治疗股份有限公司 Kras g12c抑制剂
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022187528A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline amine derivatives as kras inhibitors
WO2022228568A1 (zh) * 2021-04-30 2022-11-03 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198078A1 (zh) * 2022-04-11 2023-10-19 杭州英创医药科技有限公司 作为kras g12d抑制剂的多环化合物
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Also Published As

Publication number Publication date
CN118043330A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
US8563540B2 (en) Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
TWI772291B (zh) 取代的吡咯並嘧啶類ｃｄｋ抑制劑、包含其藥物組合物及其用途
US8653098B2 (en) Pyrazolopyridine PI3K inhibitor compounds and methods of use
WO2023051586A1 (zh) Kras g12d抑制剂化合物及其制备方法和应用
CN101981037A (zh) 吡唑并嘧啶pi3k抑制剂化合物及使用方法
MX2010014005A (es) Compuestos de triazolopiridina inhibidores de jak y los metodos.
TW200940542A (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US11267815B2 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
TWI836822B (zh) p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
WO2023198199A1 (zh) 膜缔合酪氨酸和苏氨酸激酶抑制剂
CN115466263A (zh) 三环类化合物及其用途
WO2023061478A1 (zh) 三环类化合物
CN114874234A (zh) 作为kras g12c抑制剂的三环类化合物及其应用
WO2022213980A1 (zh) Tyk2抑制剂及其用途
US20240182429A1 (en) Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
WO2020038458A1 (zh) 一类稠环三氮唑类化合物、制备方法和用途
CN114685532A (zh) 大环类化合物及其医药用途
CN113735836A (zh) 哒嗪类化合物及其应用
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN107428762A (zh) 酞嗪酮衍生物、其制备方法及用途
JP2023527204A (ja) ３，４－ジヒドロイソキノリン系化合物及びその使用
CN114805438A (zh) 含磷酰基的tyk2抑制剂化合物
WO2024055992A1 (zh) 三环化合物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22874970

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280065933.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22874970

Country of ref document: EP

Kind code of ref document: A1